PDCD1 and neoplasm: Many immune checkpoints (including TIM‐3, TIGIT, LAG3, PD‐1, CD161, and CD96) are also NK cell inhibitory receptors, and the combination of immune checkpoint inhibitors or the development of CAR‐NK based on these checkpoints seems to increase anti‐tumour efficacy.